{"id":635475,"date":"2026-04-28T04:14:07","date_gmt":"2026-04-28T04:14:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/635475\/"},"modified":"2026-04-28T04:14:07","modified_gmt":"2026-04-28T04:14:07","slug":"pro-medicus-vs-cochlear-shares","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/635475\/","title":{"rendered":"Pro Medicus vs Cochlear shares"},"content":{"rendered":"\n

Two of the biggest ASX healthcare stocks by market cap<\/a> have been heavily sold off in 2026.\u00a0<\/p>\n

At the time of writing:<\/p>\n

Pro Medicus Ltd (ASX: PME<\/a>) is down 38% year to date Cochlear Ltd (ASX: COH<\/a>) has fallen 63%.\u00a0 <\/p>\n

These heavy sell-offs have been a large contributor to the overall fall of the S&P\/ASX 200 Health Care Index (ASX: XHJ) which is down 22% in that same period.\u00a0<\/p>\n

After such a strong decline, many brokers and analysts have re-rated and adjusted their outlooks on these ASX healthcare stocks.\u00a0<\/p>\n

Let’s see which is attracting more optimism right now.\u00a0<\/p>\n

\"Devastated<\/p>\n

Image source: Getty Images<\/p>\n

Pro Medicus <\/p>\n

Pro Medicus provides medical imaging technology globally. The company is recognised as a leading supplier of radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions for medical practices and hospitals.<\/p>\n

It sits within the top 5 largest ASX healthcare companies by market cap.\u00a0<\/p>\n

However it has suffered a brutal decline over the last year, falling almost 60% from its 12-month highs reached last July, when shares were trading for $330.<\/p>\n

Yesterday, after another decline, it closed at $138.12 per share.\u00a0<\/p>\n

General consensus is that this ASX healthcare stock is now undervalued.\u00a0<\/p>\n

Yesterday, <\/a>Medallion Financial Group cited recent contract renewals on higher fees and recent share price weakness as tailwinds for the company.\u00a0<\/p>\n

Analysts at Morgans<\/a> have also recently retained their buy rating on this health imaging technology company’s shares with a price target of $210.00.<\/p>\n

The broker also is bullish on the company thanks to contract newsflow<\/a> since February which has been “exceptional”.\u00a0<\/p>\n

We re-emphasise our positive long-term conviction on the name although lower our valuation to reflect current but potentially fleeting headwinds.<\/p>\n

From yesterday’s closing price, this target indicates an upside potential of 52%.\u00a0<\/p>\n

Cochlear <\/p>\n

Cochlear is the world’s leading cochlear implant device manufacturer with around half of global market share.<\/p>\n

Its share price fell a further 2.5% yesterday, taking its year to date fall to 63%.\u00a0<\/p>\n

The bulk of this fall occurred last week<\/a> following a cut to its earnings outlook<\/a>.<\/p>\n

The announcement sent the stock price plummeting 40% in a single day session.\u00a0<\/p>\n

Despite such a heavy fall, sentiment is mixed on what’s next for this ASX healthcare stock.\u00a0<\/p>\n

It closed trading at $95.25 yesterday.<\/p>\n

Some recent price targets from experts include:\u00a0<\/p>\n

Jarden<\/a> has a share price target of $169 on Cochlear shares Macquarie’s 12-month price target is $115 (reduced from $239) Morgans<\/a> has a hold rating and target price of $107.17.\u00a0 Foolish takeaway\u00a0 <\/p>\n

When traditional blue-chip stocks fall significantly, it always attracts attention.\u00a0<\/p>\n

With a long-term view, ASX healthcare shares could be set for a recovery<\/a>, but several headwinds will need to subside.\u00a0<\/p>\n

However, those trying to buy low on these options may need to accept more volatility<\/a> in the short term.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Two of the biggest ASX healthcare stocks by market cap have been heavily sold off in 2026.\u00a0 At…\n","protected":false},"author":2,"featured_media":635476,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500,313],"class_list":["post-635475","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-health","tag-healthcare","tag-trending"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/635475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=635475"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/635475\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/635476"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=635475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=635475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=635475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}